Form 4: Carlyle Group Sells Additional Shares of QuidelOrtho Corp (QDEL) Under 10b5-1 Trading Plan

The Carlyle Group continues to reduce its stake in QuidelOrtho Corp through a pre-arranged Rule 10b5-1 trading plan.

Summary

• The Carlyle Group, a significant shareholder of QuidelOrtho Corp (QDEL), has reported the sale of shares of common stock.
• The sales occurred on July 3, 2024, and July 5, 2024.
• A total of 103,463 shares were sold across these two days.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on May 12, 2024.
• The weighted average sale prices ranged from $30.6163 to $31.40 per share.
• Following these transactions, the Carlyle Group's indirect beneficial ownership stands at 11,249,724 shares.
• The shares are held of record by Carlyle Partners VI Cayman Holdings, L.P.
• The Carlyle Group Inc. and several related entities may be deemed to share beneficial ownership but disclaim such ownership.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine transactions under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.

Future Outlook

The Carlyle Group will likely continue selling shares under the Rule 10b5-1 trading plan.

Industry Context

Share sales by major holders like Carlyle Group are common and can be driven by various factors, including portfolio rebalancing or profit-taking. The impact on QuidelOrtho's stock price will depend on market perception and the overall demand for the stock.

Comparison to Industry Standards

• It is common for large shareholders, such as private equity firms like Carlyle, to gradually reduce their holdings in portfolio companies after a certain period.
• The use of a 10b5-1 trading plan is a standard practice to allow insiders to sell shares without being accused of trading on non-public information.
• Comparable transactions would include similar share sales by major holders in other diagnostic or healthcare companies.

Stakeholder Impact

• The share sales could potentially create downward pressure on the stock price in the short term.
• The impact on other stakeholders (employees, customers, suppliers) is likely to be minimal.

Key Dates